Abbott: New Study Shows Spinal Cord Stimulation Can Reduce, Stabilize Opioid Use Among Chronic Pain Patients

New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain.


In a new study, researchers examined opioid usage data from more than 5,400 patients both prior to and after receiving an SCS system implant. In an SCS system, an implanted device similar to a pacemaker delivers low levels of electrical energy to nerve fibers, interrupting pain signals as they travel to the brain to reduce the sensation of pain. Researchers have found that average daily opioid use declined or stabilized for patients receiving a successful SCS system compared to patient use of opioids prior to an implant.

In addition, while opioid usage was not different for the two groups at time of implant, patients who underwent a successful SCS implant had significantly lower opioid use one year after their implant. Patients who had their SCS system removed saw their opioid use increase again over time.

The study, which the researchers believe makes a compelling case for considering SCS therapy earlier in the chronic pain care continuum, were presented at the 2017 North American Neuromodulation Society (NANS) annual meeting by Ashwini Sharan, M.D., director of Functional and Epilepsy Surgery at Vickie and Jack Farber Institute for Neuroscience at Jefferson and president of NANS. The study was sponsored by Abbott(No. 14 on the DiversityInc Top 50 Companies list), a global leader in the development and manufacture of SCS systems and therapy options, such as the company’s proprietary BurstDR stimulation.

Currently, more than 2.1 million people in the U.S. suffer from substance abuse related to opioid pain relievers, while worldwide an estimated 15.5 million people are now classified as opioid dependent. Chronic pain is often a driver of opioid use as patients seek relief and improvements to their quality of life. Fortunately for patients, SCS therapy has been clinically proven to offer meaningful relief to patients suffering from chronic pain.

“Given the epidemic of opioid addiction and abuse, these findings are important and confirm that spinal cord stimulation therapy can offer strong benefits for patients struggling with chronic pain,” said Sharan. “Based on these results, we concluded it may be possible to improve outcomes by offering our patients spinal cord stimulation earlier, before opioid dependence and addiction can occur.”

About the Study:

For their analysis, the research team assessed private and Medicare insurance claims data from 5,476 patients who received an SCS system to treat chronic pain associated with a host of conditions (excluding pain related to cancer). The data were collected between January 2010 and December 2014.

The data confirmed that many patients are often prescribed increasing dosages of opioids prior to receiving an SCS system. The researchers also found:

  • SCS therapy is effective for patients at any level of opioid usage prior to implantation.
  • Opioid use declined or stabilized in 70 percent of patients who received an SCS system.
  • Among patients who had their SCS system explanted, opioid use was higher at one year compared to those who continued with SCS therapy.

The researchers further suggested patient outcomes could be improved if SCS were implanted earlier in recognition of the clinical practice to provide increasing dosages of opioids over time. These conclusions help build upon prior research, such as results of a large multi-center randomized controlled trial in patients with failed back surgery syndrome (FBSS) that showed trends in opioid reduction or cessation among SCS patients. In addition, new technologies released in the U.S. in 2015 and 2016 hold promise to improve outcomes further and may reduce common complications resulting in explant such as the undesired changes in paresthesia, issues with charging, pain at the implantable pulse generator (IPG) site, and loss of pain relief.

“As our society has been seeking ways to stem opioid abuse and addition, our company offers treatment options that can reduce their exposure to opioid medication,” said Allen Burton, M.D., medical director of neuromodulation at Abbott. “Data like these are critical to helping us demonstrate that spinal cord stimulation can reduce exposure to opioids while giving patients comprehensive pain relief.”

Latest News

Hershey’s Joins Jet-Puffed and Honey Maid Brands Make National S’mores Day Extra Sweet By Giving Back $50,000 To Small, Local Restaurants

Originally published on thehersheycompany.com. Summer screams S’mores, but this year it is screaming louder than ever with approximately 10M more of the classic treat made this year compared to last1. With many of America’s beloved restaurants closed due to quarantine orders or limited in capacity due to social distancing, Americans…

Humana

Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row

Originally published on Humana.com.  LOUISVILLE, Ky.–(BUSINESS WIRE)– Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), has been named the best in Mail Order Pharmacy customer satisfaction in the J.D. Power 2020 U.S. Pharmacy Study. It’s the third consecutive year that Humana has received the prestigious honor. The study ranks…

New Jersey, Hair, Discrimination, discriminate

3 Powerful Career Advice Tips for Women in Tech

Working as a woman in tech can have its challenges, especially since the industry is still male-dominated.  Though women make up half (50%) of all U.S. workers in STEM occupations, according to research, however, Black and Hispanic workers continue to be underrepresented in the STEM workforce. Black professionals represent only…